Muscular Disorders, Atrophic clinical trials at UC Health
2 in progress, 1 open to eligible people

• Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy

  open to eligible males ages 5 years and up

  This study is a long-term study of ataluren in participants with nonsense mutation Duchenne muscular dystrophy.

  at UC Davis UCSF

• A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

  Sorry, in progress, not accepting new patients

  HOPE-2 is a double-blind clinical trial evaluating the safety and efficacy of a cell therapy called CAP-1002 in study participants with Duchenne muscular dystrophy (DMD). Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either CAP-1002 or placebo every 3 months for a total of 4 doses during a 12-month period.

  at UC Davis

Last updated: July 1, 2019